Non Small Cell Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Non Small Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Lung Cancer - Non Small Cell SquamousLung Cancer - Non Small Cell Non-Squamous
Merus B.V.180 enrolled5 locationsNCT07353957
Recruiting

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Metastatic ALK+ Non Small Cell Lung Cancer
Pfizer600 enrolled1 locationNCT05599412
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Epidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene MutationEpidermal Growth Factor+1 more
EpiBiologics110 enrolled5 locationsNCT07462377
Recruiting
Phase 1Phase 2

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 1Phase 2

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

RET-altered Non Small Cell Lung CancerRET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.244 enrolled21 locationsNCT04683250
Recruiting
Phase 1Phase 2

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Advanced Solid TumorsAdvanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer+2 more
Auricula Biosciences Inc.110 enrolled4 locationsNCT07148128
Recruiting
Phase 3

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Phase 2

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

Advanced Breast CancerAdvanced Gastric CancerAdvanced Urothelial Cancer+1 more
UNICANCER400 enrolled1 locationNCT07259226
Recruiting
Phase 2

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.170 enrolled84 locationsNCT04614103
Recruiting
Phase 1

MOv19-BBz CAR T Cells in FRa+ Cancers

Recurrent Lung Non-Small Cell CarcinomaMetastatic Non Small Cell Lung Cancer
University of Pennsylvania10 enrolled1 locationNCT07116057
Recruiting
Phase 3

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC

Oligometastatic DiseaseMetastatic Non Small Cell Lung Cancer
Tata Memorial Hospital190 enrolled1 locationNCT05278052
Recruiting

Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer

Oncogene-addicted Non Small Cell Lung CancerEarly-stage Operable Non Small Cell Lung Cancer
Royal Marsden NHS Foundation Trust100 enrolled1 locationNCT07008742
Recruiting
Phase 2

Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer Stage
University of Kansas Medical Center50 enrolled6 locationsNCT04992780
Recruiting
Phase 2

OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With Stage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection

EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
The University of Sydney100 enrolled11 locationsACTRN12623000552684